Looking at the Big Picture: Using Point-of-Care Diagnostics to Advance a One Health Approach
Konstantinos Mitsakakis, PhD, Head of International Business Development, Hahn-Schickard Institut für Mikroanalysesysteme, Freiburg, Germany
Dr. Konstantinos Mitsakakis explains the One Health approach, and how the pursuit benefits diverse avenues of diagnostic research.
Advances in Sepsis Diagnostics: the HostDx Sepsis Platform
Timothy Sweeney, MD, PhD, CEO, Inflammatix, United States
Tim Sweeney spoke to CHI to discuss his company’s work in using host response to diagnose and risk stratify patients with sepsis infections. He also discusses current shortcomings sepsis diagnostics, as well as what he sees as barriers in implementing
rapid diagnostics and how the field is moving forward to overcome these barriers.
The Challenges Manufacturers and Notified Bodies Face in Light of the Changing Regulatory Requirements in the EU
Andreas F. Stange, PhD, Vice President MHS Global IVD, TÜV SÜD, Germany
Dr. Andreas Stange of TÜV SÜD talks about the practical impact of the new IVD regulation, how it will affect manufacturers and notified bodies, challenges in validation, and practical advice to prepare for these changes in companion diagnostics.
The Role of Epigenetics in Circulating Tumour Cells – What is Its Clinical Utilities?
Evi Lianidou, PhD, Professor, Analytical Chemistry, Clinical Chemistry, Chemistry, University of Athens, Athens
Dr. Evi Lianidou outlines what she considers some of the greatest obstacles in CTC analysis. She also shares her vision for clinical utilities of epigenetics in CTC and comments on some of the most exciting new studies and emerging technologies in
CTC field, along with some advice for the CTC community in order to move liquid biopsy field forward.
Addressing Challenges in cfDNA Analysis: Technologies and Next Steps
Jorg Tost, PhD, Director, Laboratory for Epigenetics & Environment, Centre National de Genotypage, CEA – Institut de Génomique, France
Dr. Jorg Tost recently spoke to CHI to discuss his work with the ice-COLD-PCR assay and how it is addressing current challenges in cfDNA analysis. He also discusses challenges related to data, new technologies, and including other biomarkers in addition
to cfDNA for the most complete and accurate analysis. Dr. Tost is speaking at the Enabling Technologies for Cell-Free DNA Analysis conference, part of Molecular Diagnostics Europe, taking place 22-24 May 2018 in Lisbon, Portugal.
Cell-Based NIPD: Where Are We Now and Where Are We Going?
Patrizia Paterlini-Brechot, Ph.D., M.D., Cellular & Molecular Biology, University Paris Descartes
Patrizia Paterlini-Brechot spoke to CHI to discuss her work in cell-based non-invasive prenatal diagnosis and some of the challenges in commercializing this technique. She also discusses the impact commercialized NIPD tests will have on the field
of prenatal diagnosis and some of the new frontiers she expects will be next. Dr. Paterlini-Brechot is speaking at the Advances in prenatal Molecular Diagnostics meeting, part of Molecular Diagnostics Europe, taking place 22-24 May 2018 in Lisbon,
The New EU IVD Regulation – What Will It Mean for Your Lab?
David E. Barton, PhD, Chief Molecular Geneticist, National Centre for Medical Genetics, Our Lady’s Hospital for Sick Children, Ireland
Dr. David Barton summarizes the new EU IVD regulations and highlights their key features. He will explain what the ramifications of introducing these new regulations for labs and manufacturers will be and advice for people preparing for the change.
Utilizing Immune Monitoring in Next Generation Immunotherapy Trials
Thomas O. Kleen, Ph.D., Executive Vice President, Immune Monitoring, Epiontis GmbH, Germany
Dr. Thomas Kleen outlines some of the challenges biomarker discovery, discusses his role in the STIC/FDA Immunotherapy Biomarkers Taskforce, and the focus of his work at Epiontis as the Executive Vice President of Immune Monitoring in this podcast
for the Biomarkers for Immunotherapy conference at Molecular Diagnostics Europe Summit.
Redefining the Set of Solutions for Antibiotics Misuse Using Host Response-Based Diagnostics
Kfir Oved, Ph.D., Co-Founder & CTO, R&D, MeMed, Israel
Dr. Kfir Oved outlines some of the greatest obstacles to controlling antibiotic misuse, advice for introducing new products in the clinical setting, describes some of the most exciting new developments emerging for AMR, and summarizes what he
is looking forward to at the Advanced Diagnostics for Infectious Disease track at Molecular Diagnostics Europe Summit.
Point-of-Impact Testing in the Emergency Department: Rapid Diagnostics for Respiratory Viral Infections
H.G.M. Niesters, Ph.D., Director, Laboratory of Clinical Virology, University Medical Center Groningen, The Netherlands
Dr. Bert Niesters discusses how standard practice in the emergency room setting has changed for both care delivered and spread of infection, the challenges associated with giving results rapidly and impact on the cost of care. He outlines improvements
in their own system in emergency room care and plans for the future, and also talks about what he is looking forward to at the Point-of-Care Diagnostics track at Molecular Diagnostics Europe Summit.
Early Detection of Cancer: Myth or Reality?
Abhijit Patel, Ph.D., Assistant Professor, Therapeutic Radiology, Yale University, United States
Abhijit Patel of the Yale University School of Medicine recently spoke with CHI, on April 11, 2017 he will be speaking during the Cell-Free DNA in Clinical Oncology meeting at Molecular Diagnostics Europe. As a physician-scientist, Dr. Patel maintains
an active clinical radiation oncology practice. His research group at Yale is working to develop and clinically validate novel noninvasive DNA- and RNA-based cancer diagnostics.
In this podcast, Dr. Patel spoke to CHI to discuss the emerging technologies and challenges in liquid biopsy including developing robust and sensitive assays to detect early stage disease.